IP Library › Granted Patent US 12,421,300
Granted Patent B2
US 12,421,300 · App. 18/951,667 · Granted Sep 23, 2025

Preparation method and application of single-chain antibody fragment targeting SARS-CoV-2 nucleocapsid protein

Inventors: Yi Luo (Jiangsu, CN); Wenjin Hu (Jiangsu, CN); Shixiang Yang (Jiangsu, CN); Xiaolong Wang (Jiangsu, CN); Shengyang Wang (Jiangsu, CN); Huai Lin (Jiangsu, CN); Xiang Long (Jiangsu, CN)
Assignee: NANJING UNIVERSITY
C07K16/1003G01N33/56983C07K2317/622
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,421,300
App. No.
18/951,667
Granted
Sep 23, 2025
Kind
B2
Abstract

Disclosed are a preparation method and application of a single-chain antibody fragment targeting SARS-CoV-2 nucleocapsid protein, aiming to provide a single-chain antibody fragment with high affinity and strong specificity. The present disclosure obtains three single-chain antibody fragments targeting SARS-CoV-2 nucleocapsid protein through construction of a nanobody phage library and phage screening technology. The single-chain antibody fragment consists of a heavy chain variable region, a 15aa connecting peptide, and a light chain variable region connected in sequence, and has an amino acid sequence shown in SEQ ID NO: 1-SEQ ID NO: 3. The single-chain antibody fragment in the present disclosure has excellent binding performance and specificity with the SARS-CoV-2 nucleocapsid protein, can be applied to a variety of immunoassay platforms of the SARS-CoV-2, and has broad application prospects in the field of SARS-CoV-2 detection.

Claims (1)

1. A single-chain antibody fragment targeting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) nucleocapsid protein, wherein the single-chain antibody fragment has an amino acid sequence shown in SEQ ID NO: 1 or SEQ ID NO: 2 or SEQ ID NO: 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 19, 2024
From: LUO, YI; HU, WENJIN; YANG, SHIXIANG; WANG, XIAOLONG; WANG, SHENGYANG; LIN, HUAI; LONG, XIANG
To: NANJING UNIVERSITY
Reel/Frame 069312/0152 →
Priority Claims (1)
CN 202311678268.6 · Dec 8, 2023 · national
Continuity (1)
Related Publication 20250188155A1 · Jun 12, 2025
References Cited (15)
US 10822379B1 · Dimitrov · 2020 [cited by examiner]
US 10948490B1 · Van Der Werf · 2021 [cited by examiner]
US 11021531B1 · Glanville · 2021 [cited by examiner]
US 11028150B1 · Glanville · 2021 [cited by examiner]
US 11053304B1 · Glanville · 2021 [cited by examiner]
US 11054429B1 · Wang · 2021 [cited by examiner]
US 20220089691A1 · Lai et al. · 2022 [cited by applicant]
CN 113150129 · 2021 [cited by applicant]
CN 114751981 · 2022 [cited by applicant]
CN 114966017 · 2022 [cited by applicant]
CN 116478242 · 2023 [cited by applicant]
CN 117924469A · 2024 [cited by examiner]
WO 2021229561 · 2021 [cited by applicant]
James S. Terry et al., “Development of a SARS-CoV-2 nucleocapsid specific monoclonal antibody”, Virology, Feb. 1, 2021, pp. 28-37, vol. 558. [cited by applicant]
Zhen-Zhen Ma et al., “Preparation of recombinant antigen and monoclonal antibody of severe acute respiratory syndrome coronavirus 2 nucleocapsid protein”, Journal of Food Safety and Quality, Dec. 2021, with English abst… [cited by applicant]